Bard1tm1Thl/Bard1tm1Thl Brca1tm1Arge/Brca1tm1Arge
involves: 129S/SvEv * 129S1/Sv
|
abnormal developmental patterning |
J:84329
|
abnormal embryonic tissue morphology |
J:84329
|
prenatal lethality |
J:84329
|
Bard1tm2Thl/Bard1tm2Thl Brca1tm1Thl/Brca1tm1Thl Waptm1(cre)Arge/0
involves: 129/Sv * 129S1/Sv * C57BL/6J
|
increased mammary adenocarcinoma incidence |
J:134977
|
Brca1tm1Aash/Brca1tm1Aash Trp53tm1Brd/Trp53+ Tg(LGB-cre)74Acl/0
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA
|
abnormal mammary gland development |
J:119996
|
increased mammary gland ductal carcinoma incidence |
J:119996
|
increased mammary gland tumor incidence |
J:119996
|
increased salivary adenocarcinoma incidence |
J:119996
|
Brca1tm1Arge/Brca1tm1Arge Brca2tm1Arge/Brca2tm1Arge
involves: 129S/SvEv * C57BL/6
|
abnormal embryonic tissue morphology |
J:40594
|
embryonic lethality, complete penetrance |
J:40594
|
Brca1tm1Arge/Brca1tm1Arge Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
embryonic growth retardation |
J:40594
|
prenatal lethality |
J:40594
|
Brca1tm1Bhk/Brca1+ Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
C.129-Cdkn2ctm1Yxi Brca1tm1Bhk
|
abnormal mammary gland morphology |
J:198018
|
increased mammary adenocarcinoma incidence |
J:198018
|
increased mammary gland tumor incidence |
J:198018
|
increased metastatic potential |
J:198018
|
Brca1tm1Bhk/Brca1tm1Bhk Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
C.129-Cdkn2ctm1Yxi Brca1tm1Bhk
|
lethality throughout fetal growth and development, complete penetrance |
J:198018
|
Brca1tm1Brn/Brca1+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * BALB/cJ * FVB/N
|
increased mammary gland tumor incidence |
J:126551
|
Brca1tm1Brn/Brca1tm1.1Jjon Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * C57BL/6J * FVB/N
|
abnormal tumor morphology |
J:178595
|
abnormal tumor pathology |
J:178595
|
decreased mammary gland tumor incidence |
J:178595
|
decreased skin tumor incidence |
J:178595
|
decreased tumor latency |
J:178595
|
Brca1tm1Brn/Brca1tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N
|
increased ovary tumor incidence |
J:189304
|
Brca1tm1Brn/Brca1tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
|
abnormal oviduct morphology |
J:189304
|
hemorrhagic ascites |
J:189304
|
increased carcinoma incidence |
J:189304
|
increased metastatic potential |
J:189304
|
increased ovarian carcinoma incidence |
J:189304
|
increased ovary tumor incidence |
J:189304
|
Brca1tm1Brn/Brca1tm1Brn Trp53tm1Brn/Trp53+ Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * BALB/cJ * FVB/N
|
increased mammary gland tumor incidence |
J:126551
|
Brca1tm1Brn/Brca1tm1Brn Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd
|
increased cell proliferation |
J:117113
|
Brca1tm1Brn/Brca1tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * BALB/cJ * FVB/N
|
increased mammary gland tumor incidence |
J:126551
|
Brca1tm1Brn/Brca1tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * C57BL/6J * FVB/N
|
abnormal tumor morphology |
J:178595
|
abnormal tumor pathology |
J:178595
|
increased mammary gland tumor incidence |
J:178595
|
increased skin tumor incidence |
J:178595
|
increased tumor latency |
J:178595
|
Brca1tm1Cxd/Brca1tm1Cxd Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd
|
abnormal chromosome number |
J:51834
|
abnormal embryonic tissue morphology |
J:51834
|
decreased embryo size |
J:51834
|
embryonic lethality during organogenesis, complete penetrance |
J:51834
|
spontaneous chromosome breakage |
J:51834
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(KRT5-cre)5132Jlj/0 Tg(KRT5-E2F1)2Dgj/0
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal epidermal layer morphology |
J:85354
|
decreased tumor latency |
J:85354
|
increased keratinocyte proliferation |
J:85354
|
increased skin tumor incidence |
J:85354
|
increased squamous cell carcinoma incidence |
J:85354
|
preweaning lethality, incomplete penetrance |
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(KRT5-E2F1)2Dgj/0
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal epidermal layer morphology |
J:85354
|
increased keratinocyte proliferation |
J:85354
|
increased mouth tumor incidence |
J:85354
|
increased papilloma incidence |
J:85354
|
increased reproductive system tumor incidence |
J:85354
|
increased skin tumor incidence |
J:85354
|
increased squamous cell carcinoma incidence |
J:85354
|
increased tumor incidence |
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd Trp53tm1Brd/Trp53+ Tg(MMTV-cre)4Mam/0
involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB
|
increased mammary gland tumor incidence |
J:54533
|
Brca1tm1Mak/Brca1tm1Mak Cdkn1atm1Tyj/Cdkn1atm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas
|
embryonic lethality during organogenesis, complete penetrance |
J:41254
|
Brca1tm1Mak/Brca1tm1Mak Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas
|
abnormal allantois morphology |
J:41254
|
abnormal visceral yolk sac morphology |
J:41254
|
decreased embryo size |
J:41254
|
embryonic growth retardation |
J:41254
|
embryonic lethality during organogenesis, complete penetrance |
J:41254
|
failure of initiation of embryo turning |
J:41254
|
Brca1tm1Thl/Brca1tm1Thl Krastm4Tyj/Kras+ Trp53tm1Thl/Trp53tm1Thl Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
decreased tumor latency |
J:177853
|
Brca1tm1Thl/Brca1tm2Rjbr Krastm4Tyj/Kras+ Trp53tm1Thl/Trp53tm1Thl Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
decreased tumor latency |
J:177853
|
Brca1tm1Thl/Brca1tm3.1Rjbr Krastm4Tyj/Kras+ Trp53tm1Thl/Trp53tm1Thl Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
decreased tumor latency |
J:177853
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Cdkn1atm1Led/Cdkn1atm1Led
involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB
|
neonatal lethality, complete penetrance |
J:81559
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Gadd45atm1Ajf/Gadd45atm1Ajf
involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * C57BL/6
|
abnormal centrosome morphology |
J:91673
|
aneuploidy |
J:91673
|
embryonic growth retardation |
J:91673
|
exencephaly |
J:91673
|
prenatal lethality, complete penetrance |
J:91673
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Parp1tm1Zqw/Parp1tm1Zqw
involves: 129S2/SvPas * 129S6/SvEvTac
|
abnormal centrosome morphology |
J:139260
|
abnormal chromosome morphology |
J:139260
|
aneuploidy |
J:139260
|
decreased cell proliferation |
J:139260
|
decreased embryo size |
J:139260
|
decreased telomere length |
J:139260
|
exencephaly |
J:139260
|
lethality throughout fetal growth and development, complete penetrance |
J:139260
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Shld1em1Nus/Shld1em1Nus
involves: 129S6/SvEvTac * C57BL/6NCrl
|
abnormal class switch recombination |
J:307190
|
chromosomal instability |
J:307190
|
normal
mortality/aging |
J:307190
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53tm1Brd/Trp53+
involves: 129S6/SvEvTac * 129S7/SvEvBrd
|
abnormal cell cycle checkpoint function |
J:70271
|
abnormal esophageal epithelium morphology |
J:122899
|
abnormal stomach epithelium morphology |
J:122899
|
normal
endocrine/exocrine gland phenotype |
J:70271
|
enlarged thymus |
J:81541
|
increased carcinoma incidence |
J:122899
|
increased embryonic tissue cell apoptosis |
J:70271
|
increased fibroblast proliferation |
J:70271
|
increased incidence of tumors by chemical induction |
J:122899
|
increased mammary gland tumor incidence |
J:70271
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:122899
|
increased T cell derived lymphoma incidence |
J:81541
|
normal
mortality/aging |
J:70271
|
premature death |
J:81541
|
respiratory distress |
J:81541
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53tm1Brd/Trp53+
involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB
|
abnormal bone structure |
J:81559
|
abnormal male meiosis |
J:82308
|
abnormal spermatid morphology |
J:82308
|
abnormal spermatogenesis |
J:82308
|
abnormal trabecular bone morphology |
J:81559
|
arrest of male meiosis |
J:82308
|
azoospermia |
J:82308
|
decreased body weight |
J:81559
|
decreased cell proliferation |
J:81559
|
decreased compact bone thickness |
J:81559
|
decreased subcutaneous adipose tissue amount |
J:81559
|
decreased total body fat amount |
J:81559
|
delayed hair regrowth |
J:81559
|
impaired wound healing |
J:81559
|
increased male germ cell apoptosis |
J:82308
|
increased physiological sensitivity to xenobiotic |
J:81559
|
increased tumor incidence |
J:81559
|
kyphosis |
J:81559
|
meiotic nondisjunction |
J:82308
|
muscular atrophy |
J:81559
|
osteoporosis |
J:81559
|
premature aging |
J:81559
|
premature death |
J:81559
|
small testis |
J:82308
|
thin dermal layer |
J:81559
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd
|
increased T cell derived lymphoma incidence |
J:81541
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53tm3Tyj/Trp53+ Waptm1(cre)Arge/Wap+
involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
decreased tumor latency |
J:177853
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53bp1tm1Jc/Trp53bp1tm1Jc
involves: 129 * 129S6/SvEvTac
|
abnormal class switch recombination |
J:307190
|
chromosomal instability |
J:307190
|
Brca1tm2.1Cxd/Brca1tm2Rjbr Trp53tm3Tyj/Trp53+ Waptm1(cre)Arge/Wap+
involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
decreased tumor latency |
J:177853
|
Brca1tm2.1Cxd/Brca1tm3.1Rjbr Trp53tm3Tyj/Trp53+ Waptm1(cre)Arge/Wap+
involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
increased tumor latency |
J:177853
|
Brca1tm2Cxd/Brca1+ Tg(KRT5-E2F1)2Dgj/0
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal epidermal layer morphology |
J:85354
|
increased keratinocyte proliferation |
J:85354
|
increased skin tumor incidence |
J:85354
|
increased squamous cell carcinoma incidence |
J:85354
|
increased tumor incidence |
J:85354
|
Brca1tm2Cxd/Brca1tm2Cxd Pkmtm1.1Mgvh/Pkmtm1.1Mgvh Trp53tm1Brd/Trp53+ Tg(MMTV-cre)4Mam/0
involves: 129S4/SvJaeSor * 129S6/SvEvTac * 129S7/SvEvBrd * FVB/N
|
decreased tumor-free survival time |
J:205213
|
increased liver tumor incidence |
J:205213
|
increased mammary gland tumor incidence |
J:205213
|
increased metastatic potential |
J:205213
|
Brca1tm2Cxd/Brca1tm2Cxd Tg(MMTV-cre)4Mam/0 Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Esr1)#Paf/0 Trp53tm1Brd/Trp53+
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB
|
increased mammary gland tumor incidence |
J:132088
|
mammary gland alveolar hyperplasia |
J:132088
|
preneoplasia |
J:132088
|
Brca1tm2Cxd/Brca1tm2Cxd Trp53tm1Brd/Trp53+ Tg(MMTV-cre)4Mam/0
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB
|
increased mammary gland epithelial cell proliferation |
J:132088
|
increased mammary gland tumor incidence |
J:132088
|
mammary gland alveolar hyperplasia |
J:132088
|
preneoplasia |
J:132088
|
ureter obstruction |
J:132088
|
Brca1tm2Cxd/Brca1tm2Cxd Trp53bp1tm1Jc/Trp53bp1tm1Jc Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
normal
cellular phenotype |
J:197442
|
Brca1tm2Mak/Brca1tm2Mak Cdkn1atm1Tyj/Cdkn1atm1Tyj Tg(Lck-cre)548Jxm/?
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
decreased thymocyte number |
J:63282
|
normal
immune system phenotype |
J:63282
|
Brca1tm2Mak/Brca1tm2Mak Chek2tm1Mak/Chek2tm1Mak Tg(Lck-cre)548Jxm/?
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
normal
cellular phenotype |
J:90512
|
chromosomal instability |
J:90512
|
normal
immune system phenotype |
J:90512
|
increased T cell derived lymphoma incidence |
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Chek2tm1Mak/Chek2tm1Mak Tg(Wap-cre)11738Mam/?
involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL
|
increased mammary adenocarcinoma incidence |
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Tg(BCL2)36Wehi/? Tg(Lck-cre)548Jxm/?
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
chromosomal instability |
J:63282
|
normal
immune system phenotype |
J:63282
|
spontaneous chromosome breakage |
J:63282
|
Brca1tm2Mak/Brca1tm2Mak Tg(Lck-cre)548Jxm/? Tg(TcrLCMV)327Sdz/?
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
abnormal T cell number |
J:63282
|
decreased double-positive T cell number |
J:63282
|
decreased T cell proliferation |
J:63282
|
decreased thymocyte number |
J:63282
|
increased double-negative T cell number |
J:63282
|
Brca1tm2Mak/Brca1tm2Mak Tg(Lck-cre)548Jxm/? Trp53tm1Brd/Trp53tm1Brd
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
chromosomal instability |
J:63282
|
normal
immune system phenotype |
J:63282
|
increased T cell derived lymphoma incidence |
J:90512
|
premature death |
J:90512
|
spontaneous chromosome breakage |
J:63282
|
Brca1tm2Mak/Brca1tm2Mak Trp53tm1Brd/Trp53+ Tg(Wap-cre)11738Mam/?
involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL
|
increased mammary adenocarcinoma incidence |
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Trp53tm1Brd/Trp53tm1Brd Tg(Wap-cre)11738Mam/?
involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL
|
increased tumor incidence |
J:90512
|
Brca1tm3Cxd/Brca1tm3Cxd
involves: 129S6/SvEvTac * FVB/N
|
abnormal awl hair morphology |
J:94114
|
abnormal branching of the mammary ductal tree |
J:94114
|
abnormal cell cycle |
J:94114
|
abnormal ovary morphology |
J:94114
|
increased body weight |
J:94114
|
increased hepatoma incidence |
J:94114
|
increased incidence of tumors by ionizing radiation induction |
J:94114
|
increased lipoma incidence |
J:94114
|
increased lymphoma incidence |
J:94114
|
increased mammary gland tumor incidence |
J:94114
|
increased tumor incidence |
J:94114
|
uterus hyperplasia |
J:94114
|
Brca1tm4Cxd/Brca1tm4Cxd
involves: 129S6/SvEvTac * NIH Black Swiss
|
abnormal cell cycle |
J:112308
|
abnormal centrosome morphology |
J:112308
|
abnormal mammary gland duct morphology |
J:112308
|
abnormal mammary gland epithelium morphology |
J:112308
|
abnormal mammary gland morphology |
J:112308
|
abnormal uterine cervix squamous epithelium morphology |
J:112308
|
endometrium hyperplasia |
J:112308
|
increased mammary gland ductal carcinoma incidence |
J:112308
|
increased mammary gland tumor incidence |
J:112308
|
mammary gland duct hyperplasia |
J:112308
|
mammary gland hyperplasia |
J:112308
|
normal
mortality/aging |
J:112308
|